Reliferon Injection (3MIU) is a pharmaceutical preparation containing Interferon Alpha 2B, specifically formulated at a dosage of 3 million international units (3MIU) per injection. This medication is primarily utilized in the treatment of various viral infections and certain types of cancers, including hepatitis B and C, as well as specific hematological malignancies. Interferon Alpha 2B is a type of protein that plays a crucial role in the immune response, helping the body to fight off infections and tumors. The injection is typically administered subcutaneously or intramuscularly, depending on the specific medical condition being treated. Reliferon Injection is known for its ability to enhance the immune system’s response, making it a vital option in antiviral therapy and oncology. Patients receiving this treatment should be closely monitored for efficacy and potential side effects, ensuring optimal therapeutic outcomes.